SalvaRX losses deepen after asset disposal
AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Drug developer SalvaRX Group booked a deeper annual loss owing to an asset disposal.
Pre-tax losses for the year through December amounted to £3.4m, compared to losses of £2.2m on-year.
The loss came despite R&D spending falling to £861k, down from £1.19m on-year.
At 2:14pm: (LON:SALV) Salvarx Group Plc share price was -1.5p at 9p
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.
